Anti-T-cell globulin: an essential ingredient for haematopoietic cell transplantation?

The Lancet Oncology

Volumn 10, Issue 9, 2009, Pages 839-

  Frassoni, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; CANCER SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; MORBIDITY; MORTALITY; ONCOLOGY; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; T CELL DEPLETION;

ANTILYMPHOCYTE SERUM; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; T-LYMPHOCYTES;

EID: 69249117043     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70233-5     Document Type: Letter

References (4)

1. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in hematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol (2009) 10.1016/S1470-2045(09)70225-6 published online Aug 19.
2. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft versus host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947
3. Wagner J.E., Thompson J.S., Carter S.L., and Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 366 (2005) 733-741
4. Ciceri F., Bonini C., Stanghellini M.T., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 10 (2009) 489-500